期刊文献+

缬沙坦治疗早期糖尿病肾病82例临床观察 被引量:12

The influence of valsartan on MAU of patients with diabetic nephropathy(DN) at early stage
原文传递
导出
摘要 目的 探讨缬沙坦治疗早期糖尿病肾病(DN)的临床疗效及安全性.方法 163例早期DN患者按入院顺序随机分为治疗组82例和对照组81例,两组均给予常规治疗,治疗组加用缬沙坦治疗,60~80 mg/d,疗程为24周.观察比较两组微量白蛋白尿排泄率(UAER)、血清肌酐(Cr)、尿素氮(BUN)等变化情况及不良反应发生情况.结果 治疗24周后,治疗组UAER、Cr、BUN分别为(142.4±15.6)μg/min、(68.7±9.4)μmol/L、(3.5±1.2)mmol/L,较治疗前的(195.8±23.7)μg/min、(93.8±13.6)μmol/L、(6.3±1.5)mmol/L明显改善(t=13.675、11.287、2.469,均P〈0.05),较对照组治疗24周后的(199.6±24.7)μg/min、(87.7±11.3)μmol/L、(6.2±1.3)mmol/L降低更明显(t=13.246、10.312、2.518,均P〈0.05).两组均未发生严重不良反应.结论 缬沙坦治疗早期糖尿病肾病可以有效改善患者肾功能,提高治疗效果,且不良反应较少. Objective To explore influence of valsartan on MAU of patients with DN at early stage.Methods 163 patients with DN at early stage were randomly divided into experimental group and control group.Two groups were given routine therapy, and experimental group were added the therapy of valsartan.Period of treatment was 24 weeks, and compared the UAER, Cr, BUN of two groups.Results After treatment of 24 weeks, UAER, Cr, BUN of experimental groups was (142.4 ± 15.6) μg/min, ( 68.7 ±9.4) μmol/L, (3.5 ± 1.2 ) mmol/L, compared with (195.8±23.7)(μg/min,(93.8 ± 13.6) μmol/L, (6.3 ±1.5) mmol/L before treatment, had significant difference (t = 13.675,11.287,2.469,all P〈0.05).Compared with( 199.6 ±24.7)μg/min,(87.7 ±11.3)μmol/L、(6.2 ± 1.3)mmol/L of control group after treatment, declined more significantly (t = 13.246,10.312,2.518,all P〈0.05).There was no serious complications occurred in two groups.Conclusion Valsartan used in patients with DN at early stage,can significantly improve the function of kidney and enhance clinical effect,decline the side reaction.
出处 《中国基层医药》 CAS 2011年第12期1606-1607,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 糖尿病肾病 白蛋白尿 缬沙坦 Diabetic nephropathies Albuminuria Valsartan
  • 相关文献

参考文献17

二级参考文献128

共引文献116

同被引文献86

  • 1单文卫,申丽萍,常晓红.沙坦类降压药的研究现状与临床评价[J].中国心血管病研究,2009,7(8):622-625. 被引量:14
  • 2李小会,董正华,丁辉.糖尿病肾病病因病机的探讨[J].陕西中医,2005,26(6):552-553. 被引量:91
  • 3孙丽莎,韩红玲,高博.糖尿病肾病早期诊断指标的探讨[J].医学综述,2006,12(16):988-990. 被引量:32
  • 4王文凤.健脾益肾活血法治疗早期糖尿病肾病疗效观察[J].中国医药,2007,2(6):346-347. 被引量:7
  • 5Lemley KV, Abdullah I, Myers BD, et al. Evolution of incipient nephropathy in type 2 diabetes mellilus. Kidey lnt,2000,58 (3) : 1228.
  • 6Feldt-Rasmussen B. Mieroabumina, endothelial dysfunction and cardiovascular risk. Diabetes Metab ,2000,26 ( Suppl 4) :64-66.
  • 7Sasski A, Oikawas ,Toyota T. Mieroabuminuria is closely related to diabetic macroangiopathy, Diabetes Res Cli Pract, 1999,44 ( 1 ) : 35-40.
  • 8Schalkwijk CG, Stehouwer CD. Vascular complication in diabetes melitus the role of endothlial dysfunction, eli sci( Lond ), 2005, 109(2) : 143-159.
  • 9中华人民兵和同卫生部心血管病研究中心.中国高血压防治指南(2009年修订版).北京:人民卫生出版社,2009:85-88.
  • 10Pickering TG, White WB, Giles TD, et al. When and how to use self(home) and ambulatory blood pressure monitoring. J Am Soc Hypertens,2010,4 (2) :56-61.

引证文献12

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部